Extended Half-Life Formulations Transforming Treatment Paradigms in the Long Acting Growth Hormone Lagh Market
Transitioning from burdensome daily subcutaneous injections to once-weekly sustained-release formulations is driving adoption across the Long Acting Growth Hormone Lagh Market. Pediatric and adult growth hormone deficiency (GHD) management requires long-term adherence to recombinant human growth hormone (rhGH) therapy. Novel long-acting technologies—including pegylation, prodrug...
0 Commenti 0 condivisioni 180 Views 0 Anteprima